NVAX•benzinga•
Novavax Reiterates Expectation To Achieve R&D Plus SG&A Expenses For FY25 Of Between $475M-$525M. For 2026 And 2027, Expects To Reduce R&D Plus SG&A Expenses To Approximately $350M And $250M, Respectively
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 19, 2025 by benzinga